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Abstract
Background: Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy. Disregulation of
Eph/ephrin signaling has been implicated in oncogenesis and tumor progression. EphA5 receptor is one of large
families of Eph tyrosine kinase receptor and is documented in the development of nervous system. Till now, there
is no published data about the role of EphA5 in ovarian epithelial neoplasmas.
Methods: This study aims to investigate the expression of EphA5 protein in ovarian serous carcinoma, and its
relationship to clinical pathological characteristics. Sixty-one cases of ovarian serous carcinoma, 24 cases of benign
ovarian serous tumors, 42 cases of serous borderline tumors and 20 cases of normal fallopian tubes were examined
using immunohistochemical staining. The relationship between EphA5 expression and pathological parameters was
analyzed. Kaplan-Meier survival function was used to analyze prognosis of patients.
Results: Immunostaining analysis demonstrated that the EphA5 protein was highly expressed in 100% (20/20) of
normal fallopian tube samples, 100% (24/24) of benign epithelial ovarian tumors, 76% (32/42) of ovarian serous
borderline tumors, and 31% (19/61) of ovarian serous carcinomas. Loss of EphA5expression was associated with
tumor grade (P < 0.001) and FIGO stage (P = 0.005). The survival analysis showed that patients with negative or
weak expression of EphA5 protein had a poor outcome than those with positive expression (P = 0.004).
Conclusions: Our results show that EphA5 may be a potential biomarker for distinguishing high-and low-grade
ovarian serous carcinoma and a potential prognostic marker.
Keywords: EphA5, Receptor tyrosine kinase, Ovarian serous carcinoma
Background
Epithelial ovarian cancer (EOC) is the most lethal
gynecological malignancy and the fifth common cause of
tumor-related death in women in the United States. The
survival rates for advanced stage of the disease that have
not changed in several decades [1, 2]. Lack of specific
symptoms of the disease in its early stages is a significant
factor contributing to the high mortality rate. Conse-
quently, most patients have reached advanced stage at the
time of diagnosis [3]. Despite new diagnostic and surgical
advances, and development of chemotherapeutic regimens,
the overall 5-year survival for women with advanced stage
epithelial ovarian cancer has remained approximately 12%
over the past 40 years [4]. Ovarian serous carcinoma (OSC)
is a common ovarian epithelial malignancy, which has trad-
itionally been graded as high, moderately, and poorly differ-
entiated, indicating that it is a homogeneous disease in the
position of pathogenesis. More recently, a 2-tier grading
system has been proposed, in which ovarian serous carcin-
omas are subdivided into low-grade and high-grade. Sem-
inal clinicopathologic and molecular genetic studies have
revealed that this approach is simplistic, reproducible, and
on the basis of underlying morphologic and molecular gen-
etic differences between low-grade and high-grade tumors
[5]. The progression to invasive carcinoma is a slow step-
wise process. Low-grade tumors are indolent and have
better outcome than high-grade tumors [6]. Notwithstand-
ing the enormous effort, the etiopathogenesis of epithelial
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ovarian cancers are still unknown. The development of
more effective therapeutic strategies highlight the need to
better understand the molecular mechanisms of ovarian
cancer.
The Eph (Erythropoietin-producing human hepatocellu-
lar carcinoma cell) family of receptors and ligands is the
largest group of tyrosine kinase receptor-ligand systems,
which is involved in many physiological roles including
axon guidance, neural plasticity, angiogenesis, cell migra-
tion and tissue segmentation [7, 8]. Based on the struc-
tural homology and the binding affinities, The Eph
receptors and their ephrin ligands are classified into two
groups, A and B. Ephrin-A ligands generally bind to EphA
receptors via a glycosylphosphatidylinositol anchor on the
cell membrane, whereas ephrin-B ligands bind to EphB re-
ceptors via a transmembrane domain [9]. Eph receptors
have been implicated in mediating developmental events,
particularly in the nervous system. The roles of the Eph
receptors and ephrin ligands in cell adhesion, migration,
formation of the borders of compartments, regulation of
cell proliferation in various tumors and angiogenesis are
also well documented [10, 11]. EphA5 (also known as
REK7, Ehk-1, Bsk) is a member of the Eph receptor tyro-
sine kinase subfamily, originally identified as a nervous-
system-specific orphan receptor expressed in embryonic
rats at high levels and in the adult brain at lower levels
[12]. The function of the EphA5 receptor is well estab-
lished as an axon guidance molecule during neural system
development [13]. However, the potential role of EphA5
in human carcinogenesis has not been well addressed. Fu
et al. revealed that increased methylation of EphA5 is cor-
related with decreased expression in primary breast cancer
[14]. Giaginis et al. found that pancreatic adenocarcinoma
cases with enhanced EphA5 expression presented signifi-
cantly increased tumor cells proliferative capacity [15]. To
date, there have been no published reports describing the
role of EphA5 expression in epithelial ovarian carcinoma.
Here, we evaluated the expression of EphA5 protein in a
set of normal fallopian tube, benign epithelial ovarian tu-
mors, ovarian serous borderline tumors, and ovarian ser-
ous carcinomas samples to explore its roles in ovarian
serous carcinoma.
Methods
Patients and clinicopathological variables
The study cohort consisted of 61 patients with ovarian
serous carcinoma (age range 25–69 years, mean age
50 years; high-grade 40, low-grade 21), 24 patients with
benign ovarian serous tumors (age range 23–62 years,
mean age 34 years), 42 patients with ovarian serous bor-
derline tumors (age range 19–45years, mean age 33 years)
and 20 normal fallopian tube tissue samples obtained from
patients (age range 46–57 years, mean age 47 years) who
underwent surgery for benign gynecological diseases from
2005 to 2014 in Jinling Hospital, Nanjing, China. All
hematoxylin and eosin stained slides were reviewed by
two pathologists to verify the diagnosis, histological grade
and stage. Pathological stage and histological subtype were
determined for each surgical specimen according to the
2002 International Federation of Gynecology and Obstet-
rics (FIGO) criteria, and Pathology and Genetics Tumors
of the Breast and Female Genital Organs (World Health
Organization, WHO 2003). A two-tier (low-grade and
high-grade) system was used to define the differentiation
of ovarian serous carcinomas. Patient data were obtained
from hospital tumor registry and telephone review. None
of the patients received preoperative chemotherapy or ra-
diation therapy. All cases of recurrence had radio-graphic
evidence of disease or biopsy proven progression of dis-
ease. Sixty-one patients with ovarian serous carcinoma
were followed up until April 2015. The records of patients
who were alive at follow-up or who did not die of disease
were considered to be censored. Ethical approval was
obtained from Ethics Committee of Jinling Hospital,
Nanjing, China (2016NZGKJ-075).
Immunohistochemistry
Sections from surgical specimens were fixed in 10% forma-
lin and embedded in paraffin and were used for immuno-
histochemical staining (IHC) according to a standard
method. Briefly, each 4-μm tissue section was deparaffi-
nized and rehydrated. After rehydration through a graded
ethanol series, the sections were autoclaved in 10 mM cit-
rate buffer (pH 6.0) at 120 °C for 2 min for antigen retrieval,
then cooled to 30 °C and washed with phosphate-buffered
saline (PBS, pH 7.3). After endogenous peroxidase had been
quenched with aqueous 3% H2O2 for 10 min, the sections
were washed with PBS, incubated at 4 °C overnight with
primary rabbit polyclonal anti-EphA5 antibody (Abgent,
San Diego, CA, USA) at a dilution of 1:600 and then
washed with PBS. The sections were incubated with sec-
ondary antibody (Dako REAL EnVision Detection System,
Dako, UK) for 30 min at room temperature. This was
followed by color development with 3, 3′-diaminobenzidine
(DAB) solution for 1 min. Nuclei were lightly counter-
stained with hematoxylin. The lung cancer with known
positivity was used as a positive external control (Fig. 1f).
Primary antibody was replaced with antibody diluent for
negative controls (Fig. 1g). PAX8 and cytokeratin protein
were checked in high and low grade serous ovarian carcin-
omas (Fig. 2).
EphA5 staining was independently evaluated for immu-
noreactivity by two pathologists who were double-blinded
to clinical data according to the scoring criteria. Immuno-
histochemical staining of cancer cells was assessed accord-
ing to the staining intensity of positive cells. EphA5
expression was assessed for intensity (0 = no staining, 1 + =
weak, 2 + =moderate, 3 + = strong).
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Statistical analysis
The statistical significance of intergroup differences was
evaluated by Spearman correlation analysis. Survival curves
were constructed using the Kaplan-Meier method and the
differences between the curves were compared by the log-
rank test. A multivariate Cox proportional hazards model
was used to analyze independent influence of EphA5 gene
in survival. P-values <0.05 (two-sided) were considered sta-
tistically significant. All analyses were performed by SPSS
software (version 16.0, Chicago, IL).
Fig. 1 Expression of EphA5 in normal fallopian tube and ovarian serous tumors. a High expression of EphA5 in normal fallopian tube. b High
expression of EphA5 in benign serous tumor. c High expression of EphA5 in serous borderline tumor. d High expression of EphA5 in low-grade
serous carcinoma. e Low expression of EphA5 in high-grade serous carcinoma. f Positive control (lung adenocarcinoma). g Negative control
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Results
EphA5 expression in fallopian tube, ovarian benign,
borderline and serous carcinoma
The expression of EphA5 protein was determined in
ovarian epithelial tumors and normal fallopian tube by
immunohistochemical staining (Fig. 1). As shown in Figs. 1
and 2, EphA5 staining was predominantly localized in the
cytoplasm. High and moderate expression of EphA5 was
observed in 100% (20/20) of normal fallopian tube sam-
ples, 100% (24/24) of benign epithelial ovarian tumors,
76% (32/42) of ovarian serous borderline tumors, and 31%
(19/61) of ovarian serous carcinomas. The expression of
Fig. 2 Representative examples of expression of EphA5, PAX8 and cytokeratin in low- and high-grade ovarian serous carcinomas. a and e: h and
e staining of low- and high-grade ovarian serous carcinoma. b and f: Staining of EphA5; c and g: staining of PAX8; d and h: staining of cytokeratin
in low- and high-grade ovarian serous carcinoma
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EphA5 protein was significantly decreased from normal fal-
lopian tubes, benign ovarian serous tumors, ovarian serous
borderline tumors to ovarian serous carcinomas (P < 0.001)
(Table 1).
EphA5 expression in ovarian serous carcinoma and its
correlation with clinicopathological parameters
EphA5 protein was differentially expressed in 61 samples of
ovarian serous carcinoma. Forty-two of 61 (68.9%) samples
were negatively or weakly (0/1+) stained with anti-Eph A5
antibody, 15 of 61samples (24.6%) were moderately stained
(2+) and 4 of 61 samples (6.6%) were strongly stained (3+).
The expression of EphA5 was decreased in ovarian serous
carcinoma compared with normal fallopian tube. The
relationship between EphA5 expression and pathological
parameters was analyzed (Table 2). Expression of EphA5
was significantly associated with grade (P < 0.001) and
FIGO stage (P = 0.005). No significant relationship was
observed between the expression of EphA5 and age (P =
0.178), diameter (P = 0.140) and metastasis (P = 0.168).
Association between EphA5 expression and overall
survival in patients with serous ovarian cancer
Fifty-three cases stained for EphA5 had follow-up data for
survival and were available for assessment. Using the
follow-up data of the 53 patients in conjunction with the
results from the EphA5 IHC staining experiments, we
showed that patients with high expression had a signifi-
cantly favorable overall survival (OS) compared to patients
with negative or weak expression (P = 0.004, Fig. 3). Data
from Cox proportional hazards model indicated that
EphA5 expression (P = 0.049, HR = 2.532, 95% CI = 0.104–
2.722) and FIGO stage (P = 0.006, HR = 5.290, 95% CI =
1.413–7.659) are independent influences in prediction of
survival.
Discussion
EphA5 plays a role in spine formation and synaptogenesis.
In contrast to these more established roles, EphA5 function
in cancer is much less clear. Fu et al. [14] found that the
level of EphA5 mRNA was dramatically decreased in 5
breast cancer cell lines. Previously, we detected the EphB6
protein in ovarian serous carcinoma. Decreased expression
of EphB6 was found in ovarian serous carcinomas
compared with that in normal fallopian tubes. The loss of
EphB6 protein was associated with higher tumor grade and
TNM stage [16]. In current study, we found that loss of ex-
pression of EphA5 was more often found in high-grade and
advanced FIGO stage in ovarian serous carcinoma. Women
with low-grade serous ovarian carcinoma are younger and
have longer survival than women with high-grade tumors.
It is crucial to separate women with serous ovarian carcin-
oma into 2 clinically distinct populations, low-grade and
high-grade, as they deserve unique consideration of and
treatment for their specific histotypes [17–19]. Our findings
that EphA5 was absent in high-grade serous ovarian carcin-
oma indicate that EphA5 may be a new biomarker for dis-
tinguishing high- and low-grade ovarian serous carcinoma.
The data was consistent with the survival analysis that
negative or weak expression of EphA5 protein had a poorer
outcome than those with high expression.
DNA methylation at promoter region is a powerful epi-
genetic modification regulates gene transcription. EphA5
gene silenced by methylation has been demonstrated in
breast cancer [14], prostate cancer [20], and colorectal
cancer [21], implying that the hypermethylation of EphA5
might be of great importance during tumorigenesis and pro-
gression in cancer. Identification of hypermethylated EphA5
DNA in ovarian serous carcinoma will improve our under-
standing of the mechanisms leading to the downregulation
of EphA5 expression in ovarian tumorigenesis and can serve
as valuable diagnostic marker. In our next study, we will
Table 1 The expression of EphA5 in fallopian tube, ovarian
benign tumor, border line tumor and serous carcinoma
Parameters No. EphA5 protein expression P value
147 0/1+ 2+ 3+
Fallopian tube 20 0 0 20
Benign tumor 24 0 1 23
Borderline tumor 42 10 25 7
Ovarian serous carcinoma 61 42 15 4 <0.001
Table 2 The relationship between the expression of EphA5 and
clinicopathological parameters of ovarian serous carcinoma
Parameters No. EphA5 protein expression P Value
61 0/1+ 2+ 3+
FIGO Stage 0.005
I + II 26 13 10 3
III + IV 35 29 5 1
Grade
high 40 38 2 0 <0.001
low 21 4 13 4
Diemeter (cm) 0.140
≤ 5 16 13 3 0
5–10 32 21 7 4
> 10 13 7 6 0
Age (years) 0.178
< 50 29 17 11 1
≥ 50 32 25 4 3
Metastasis 0.168
Yes 37 28 8 1
No 17 7 8 2
Not available 7 6 0 1
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determine the relationship between expression level and the
methylation status of EphA5 in ovarian cancer tissues.
It is now widely accepted that low-grade and high-grade
serous tumors are essentially distinct diseases. They exhibit
distinct genetic alterations, molecular patterns and clinical
behavior. Clinically, high-grade serous carcinoma are ag-
gressive neoplasms which frequently affect women in the
perimenopausal or postmenopausal age group, while low-
grade serous carcinomas are relatively indolent and affect
younger women. Low-grade serous carcinomas are more
refractory to platinum-based chemotherapy than high-
grade serous carcinoma. High-grade and low-grade serous
carcinomas are usually easily distinguished, it may be diffi-
cult when nuclear features are intermediate between grade
1 and grade 3; and in small tissue samples.
Conclusions
Our results show that EphA5 is a potential biomarker
for distinguishing high-and low-grade ovarian serous
carcinoma, and a potential prognostic marker in ovarian
serous carcinomas.
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